Skip to Main Content
Services Talent Knowledge
Site Search
Menu

Alert

Our attorneys stay on top of changes in legislation, agency regulations, case law, and industry trends—then craft timely legal alerts to keep clients up to date on legal developments important to their business.

December 17, 2021

Second Department Determines Exclusion of Test Results Not Harmless in Medical Malpractice Action

Recently, the Second Department in Walsh v. Akhund1  determined that the trial court’s exclusion of test results indicating that the decedent’s sister carried the harmful variant of the BRCA2 gene was not harmless. Consequently, the Second Department reversed and remitted the case for a new trial.

In Walsh, the plaintiff filed an action to recover damages for medical malpractice and wrongful death after the plaintiff’s decedent was treated for breast cancer by the defendants in 2002, eventually developed ovarian cancer sometime prior to July 10, 2007, and passed away in September 2007.  

In January 2008, the decedent’s sister underwent genetic testing and tested positive for a harmful variant of the BRCA2 gene.

At trial, the plaintiff sought to demonstrate that the defendants deviated from accepted medical practice by failing to advise the decedent to seek genetic counseling that may have disclosed that the decedent had a harmful variant of the BRCA1 or BRCA2 gene, substantially increasing her risk of developing ovarian cancer.  

The trial court granted a motion in limine to preclude the introduction of the decedent’s sister’s test results as highly speculative; the jury found that, while the oncologist failed to provide information regarding genetic counseling to the plaintiff, the departure was not a substantial factor in causing the decedent’s injury or death.  

On appeal, although the Second Department recognized that trial courts have wide discretion in making evidentiary rulings, it determined that the evidence that the decedent’s sister tested positive for the harmful variant of the BRCA2 gene was not unduly prejudicial and was relevant to the issue of proximate cause. The court further concluded that the evidence would have contradicted the defendants’ position that “the decedent’s chances of testing positive for the harmful gene variant were as low as 2.5 to 5 percent.”  

This decision demonstrates that, despite the broad discretion afforded to trial courts in making evidentiary rulings, reversal is warranted where the exclusion of evidence is unduly prejudicial.  

If you have any questions regarding the content of this alert, please contact Elizabeth Vulaj, associate, at evulaj@barclaydamon.com; Tara Sciortino, counsel, at 
tsciortino@barclaydamon.com; or another member of the Torts & Products Liability Defense Practice Area.

 

                                                      

12021 NY Slip Op. 05890

Subscribe

Click here to sign up for alerts, blog posts, and firm news.

Featured Media

Alerts

Key Affordable-Housing Provisions in the One Big Beautiful Bill Act

Alerts

What the One Big Beautiful Bill Act Means for Clean-Energy Tax Credits

Alerts

One Big Beautiful Bill Act Changes Tax Incentives for Charitable Giving

Alerts

Website Accessibility Lawsuits: Several "Tester" Plaintiffs—Wislande Claude, Felipe Fernandez, Howard Wilson, Lisa Cantwell, and Erika Alexandria—Targeting Businesses in Recent Flurry of Lawsuits

Alerts

NYS Appellate Court Holds Family Members Are Not Bound by Arbitration Agreement Signed by Deceased Relative

Alerts

Website Accessibility Lawsuits: Several "Tester" Plaintiffs—Milagros Senior, Sylinia Jackson, Edery Herrera, Henry Tucker, and Carlton Knowles—Targeting Businesses in Recent Flurry of Lawsuits